Pseudomonas aeruginosa infection is associated with poorer outcomes in non-cystic fibrosis bronchiectasis. It is unknown whether early eradication improves outcomes. This retrospective study assessed clinical and microbiological outcomes of eradication therapy following initial Pseudomonas infection.
Introduction
Bronchiectasis is a disease characterised by dilated bronchi, airway inflammation and bacterial colonisation. Recurrent exacerbations caused by bacterial infection lead to increased morbidity. Chronic infection with Pseudomonas aeruginosa commonly occurs as the disease progresses and is associated with increased symptoms, 1 decreased quality of life 2 and possibly a decline in FEV1. 3, 4 Treatment of exacerbations in patients infected with Pseudomonas often requires hospital admission for intravenous antibiotics as the organism is frequently resistant to oral antibiotics.
In patients with cystic fibrosis (CF), early treatment of Pseudomonas following first culture is well established as it reduces risk of chronic colonisation, which in this population is similarly associated with poorer outcomes. 5 Several small randomised controlled trials in CF patients showed that microbiological eradication was more likely following treatment with combined nebulised colistin and oral ciprofloxacin, or nebulised tobramycin, 6e9 although the most effective treatment strategy has not been determined. 5 Based on this, it could be postulated that early treatment in non-CF bronchiectasis would also improve outcomes. Indeed, recent British Thoracic Society guidelines recommend attempting early Pseudomonas eradication, initially with high dose oral ciprofloxacin, and second line treatment with further oral, intravenous or nebulised anti-Pseudomonal antibiotics. 10 Despite this however, there are no existing studies non-CF bronchiectasis assessing eradication therapy in recently infected patients.
Since 2004, our unit has had a policy of early Pseudomonas eradication therapy in patients with non-CF bronchiectasis. This retrospective study examines the clinical and microbiological outcomes of this treatment strategy.
Methods

Study centre
The study was carried out in a UK District General Hospital serving a population of 500,000. The Respiratory Unit is well established and offers a secondary care service for all respiratory conditions, including non-CF bronchiectasis.
Patient selection
Patients with bronchiectasis who had undergone "Pseudomonas eradication therapy" were identified retrospectively from electronic case records at the Royal United Hospital, Bath for the period January 2004 to January 2010. Patients were under standard hospital clinic follow up. Patients were included in the study if they had: (i) a diagnosis of bronchiectasis as based on clinical presentation and HRCT findings; and (ii) first attempt at Pseudomonas eradication as per protocol. Decision to commence eradication therapy was at the clinician's discretion, typically after the second isolate of Pseudomonas from sputum. Patients were also included in the study if they had had more than two cultures of Pseudomonas but had not previously had eradication therapy. Patients who were commenced on regular nebulised antipseudomonal antibiotics without concurrent intravenous or oral antibiotics were not included.
Pseudomonas eradication protocol
Intravenous regime: Intravenous gentamicin 4 mg/kg plus ceftazidime 2 g three times daily for 2-weeks, followed by nebulised colistin 2 megaunits twice daily for 3 months þ/À oral ciprofloxacin 500 mg twice daily for 3 months.
Oral regime: Ciprofloxacin 500 mg twice daily for 3 months plus nebulised colistin 2 megaunits twice daily for 3 months.
Variations from the protocol occurred mainly because of drug allergy or intolerance, and alternative antipseudomonal antibiotics were used at the clinician's discretion.
Sputum cultures
Sputum was analysed in the hospital microbiology laboratory as per standard methods, including antibiotic sensitivities. 11 Sputum samples from patients with bronchiectasis were highlighted to the laboratory to ensure appropriate culture for Pseudomonas. Following completion of treatment, eradication of Pseudomonas was defined as a negative culture on next sputum sample taken. Recurrence was defined as the first positive culture following treatment. Sputum cultures were collected at next point of clinical contact following treatment. Pseudomonas antibiotic sensitivities for pairs of sputum samples before and after eradication therapy for the patients in whom eradication was successful, but who were subsequently recolonised, were recorded, to determine if eradication therapy resulted in resistant strains.
Exacerbation frequency and hospital admissions
Number of episodes was recorded for the years pre-and post-eradication. An exacerbation was defined as an episode of increased symptoms of bronchiectasis requiring a course of oral or intravenous antibiotics. Data on antibiotic courses was obtained from hospital records and GP prescriptions. A hospital admission was defined as an increase in symptoms of bronchiectasis requiring admission to hospital for intravenous antibiotics.
Spirometry
This was performed in the lung function laboratory using a standard spirometer (ZAN 100, nSpire) at routine clinic visits and was recorded as percentage predicted, based on standard prediction charts. 12 
Statistical analysis
Comparison of parametric data was made using Student's t-test and of non-parametric data using the ManneWhitney U test. Significant p-value was taken to be <0.05.
Results
Patient demographics 30 patients were identified and characteristics are shown in Table 1 . Median follow-up time was 26.4 months. The median number of sputum cultures per patient positive for Pseudomonas prior to treatment was 2.0 (range 1e9) with median time from first positive culture to treatment of 7.2 months (range 0.3e33.7 months). Computerised data on historical sputum results was not available for 9 of the earliest cases.
Antibiotic regimes
25 patients received two weeks of intravenous anti-Pseudomonal antibiotics and following this, 13 patients also received oral ciprofloxacin (Table 2A and B). The remaining 5 patients received oral ciprofloxacin without intravenous antibiotics. Following intravenous and/or oral antibiotics, 25 patients received nebulised colistin. The reasons for the 5 patients not receiving colistin were intolerance of the drug (n Z 3) and clinician's decision (n Z 2). 9 patients were maintained on regular nebulised colistin following eradication therapy, nebulised antibiotics were restarted within a year of eradication in a further 4 patients (colistin n Z 2, gentamicin n Z 2), and restarted over one year from eradication in 6 patients (colistin n Z 5, gentamicin n Z 1).
Pseudomonas eradication
Pseudomonas was initially eradicated from sputum in 24 patients (80%). 13/24 patients remained Pseudomonas-free at their latest follow-up (median 14.3 months). 11/24 patients subsequently re-cultured Pseudomonas with median time to reinfection 6.2 months (Fig. 1 ).
Pseudomonas antibiotic sensitivities
Antibiotic sensitivities were recorded in the 11 patients in whom Pseudomonas was initially eradicated, and who were subsequently recolonised. In 6/11 patients, Pseudomonas remained fully sensitive (including to ciprofloxacin) following treatment. In four patients, new antibiotic resistance occurred: aztreonam (n Z 1), ciprofloxacin (n Z 1), ciprofloxacin and gentamicin (n Z 1), amikacin and gentamicin (n Z 1). Sensitivities were not available for one patient. One patient cultured MRSA and another Stenotrophomonas maltophilia following eradication therapy.
Exacerbations and admissions
Exacerbation frequency was significantly reduced, with mean number of antibiotic courses 3.93 in the year preeradication, and 2.09 in the year post-eradication (p Z 0.002) ( Table 3 ). Mean number of hospital admissions were 0.39 in the year pre-eradication and 0.29 in the year post-eradication (p Z NS). When divided into patients who were Pseudomonas-free and those who were colonised, there was a reduction in exacerbations in both groups although it was only significant in the colonised group. Admissions were reduced only in the Pseudomonas-free group, but this did not reach significance.
Spirometry
Lung function remained unchanged, with mean percentage predicted FEV1 62.1% pre-and 64.1% post-eradication (p Z NS).
Discussion
To our knowledge this is the first study to assess the effects of eradication therapy initiated after first colonisation of Pseudomonas in non-CF bronchiectasis. Although previous studies have studied use of nebulised antibiotics in this patient population they have focussed on patients with chronic, or established, Pseudomonas infection. 13e17 The results of this study suggest that early use of aggressive antibiotic therapy may not only be initially more successful in eradicating this organism, but may also have a beneficial effect on subsequent exacerbation rates.
Early and aggressive use of antibiotics in our patient population led to Pseudomonas eradication in 80% of patients, with clearance maintained in 50% of cases at 12 months and 30% at 70 months. These eradication rates compare favourably with other studies in which initial eradication rates of just 22e35% were achieved. 13, 18 This superior efficacy may relate to our use of a more aggressive antibiotic regime at an earlier stage, although clearly an alternative explanation may be that these patients simply had less severe disease than those from previously reported studies. In the majority of patients recolonised with Pseudomonas, the organism remained fully sensitive. In the four patients in whom resistance developed, it was only to one or two antibiotics, and therefore did not significantly affect future treatment options.
Use of early eradication therapy in this study significantly reduced exacerbation rates overall, suggesting that this intervention also had a meaningful clinical impact on disease behaviour. Subgroup analysis suggested a reduction in exacerbations in both those who remained Pseudomonas-free and those who were colonised, although only the reduction in the latter group was statistically significant. This apparent lack of significance in the Pseudomonas-free group should be interpreted with caution given the small numbers of patients involved. It is possible that the reduction in exacerbations in those patients who remained colonised may have been due to the effect of the subsequent long-term nebulised antibiotics, rather than eradication therapy itself, as this intervention has previously been shown to reduce exacerbations. 14 Overall admission rates in our study were not reduced following eradication therapy. This is in contrast to previous studies of nebulised antibiotics in chronic infection. 15, 16 However, our patient cohort had a low hospital admission rate pre-eradication therapy, presumably because they were in the earlier stages of their disease. Given this, it would be more difficult to demonstrate an impact on admission rates. There was a trend towards reduced admissions in the group in which Pseudomonas had been successfully eradicated, but this did not reach statistical significance. Interpretation must be limited given the small patient numbers and the potential confounder of a postantibiotic effect rather than eradication per se.
We acknowledge the limitations in this retrospective study involving a relatively small number of patients. Although there was a standardised Unit protocol for eradication therapy, treatment regimes varied between patients making it difficult to draw definite conclusions about individual antibiotic therapies. Nonetheless, the majority of patients received intravenous and nebulised antibiotics for two weeks and three months respectively, with ciprofloxacin use accounting for the main differences. Although not all patients received the same intravenous antibiotics, all but two received two concurrent anti-Pseudomonal agents, and thus efficacy is likely to be similar irrespective of which antibiotic was used. These variations reflected normal clinical practice, with reasons such as patient preference regarding treatment regime and antibiotic sideeffects accounting for most deviations from protocol.
Although most patients received eradication therapy soon after their first or second positive culture, there was a delay in initiating therapy in some patients. This reflected everyday clinical practice as some of the latter group of patients had less severe symptoms and elected not to undergo eradication therapy initially. It was usual practice to collect samples following completion of treatment. However, the timing of subsequent sputum samples was usually at next point of clinical contact, rather than at specified times. We acknowledge that variations in timings of sample collection may have affected the reported time to reinfection. This retrospective study is prone to selection bias. However, this is less likely as eradication therapy is well established in our unit and offered to all patients who culture Pseudomonas. As the study was carried out in a District General Hospital setting, we feel that our study population was representative of the standard non-CF bronchiectatic patient and thus applicable to everyday practice.
Pseudomonas infection in non-CF bronchiectasis is a common clinical problem, yet there have been no randomised controlled trials examining use of eradication therapy in those recently infected. Instead current practice is based on studies of treatment for chronic Pseudomonas infection, data extrapolated from CF patients and expert opinion. A prospective randomised controlled trial would allow consistent treatment regimes, controlled timing of sputum samples and more accurate data on symptoms. Based on the results of this study, an intravenous and nebulised antibiotic regime may be appropriate, with or without additional ciprofloxacin. However, a more conservative approach using ciprofloxacin and nebulised colistin, the regime commonly used in CF, remains an alternative.
Despite its limitations this retrospective study provides initial evidence that early Pseudomonas eradication therapy in non-CF bronchiectasis may be effective. Prospective randomised trials are now needed to answer this important clinical question.
